Home Cart Sign in  
Chemical Structure| 33419-42-0 Chemical Structure| 33419-42-0

Structure of Etoposide
CAS No.: 33419-42-0

Chemical Structure| 33419-42-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Etoposide inhibits DNA synthesis by inhibiting topoisomerase II (IC50 = 60.3 μM).

Synonyms: VP-16; VP-16-213; NSC 141540

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Andressa Santana Santos ; Vinícius Alexandre Fiaia Costa ; Vivianny Aparecida Queiroz Freitas ; Laura Raniere Borges dos Anjos ; Eder Soares de Almeida Santos ; Thales Domingos Arantes , et al.

Abstract: Sporotrichosis is recognized as the predominant subcutaneous mycosis in South America, attributed to pathogenic species within the Sporothrix genus. Notably, in Brazil, Sporothrix brasiliensis emerges as the principal species, exhibiting significant sapronotic, zoonotic and enzootic epidemic potential. Consequently, the discovery of novel therapeutic agents for the treatment of sporotrichosis is imperative. The present study is dedicated to the repositioning of pharmaceuticals for sporotrichosis therapy. To achieve this goal, we designed a pipeline with the following steps: (a) compilation and preparation of Sporothrix genome data; (b) identification of orthologous proteins among the species; (c) identification of homologous proteins in publicly available drug-target databases; (d) selection of Sporothrix essential targets using validated genes from Saccharomyces cerevisiae; (e) molecular modeling studies; and (f) experimental validation of selected candidates. Based on this approach, we were able to prioritize eight drugs for in vitro experimental validation. Among the evaluated compounds, everolimus and bifonazole demonstrated minimum inhibitory concentration (MIC) values of 0.5 µg/mL and 4.0 µg/mL, respectively. Subsequently, molecular docking studies suggest that bifonazole and everolimus may target specific proteins within S. brasiliensis– namely, sterol 14-α-demethylase and serine/threonine-protein kinase TOR, respectively. These findings shed light on the potential binding affinities and binding modes of bifonazole and everolimus with their probable targets, providing a preliminary understanding of the antifungal mechanism of action of these compounds. In conclusion, our research advances the understanding of the therapeutic potential of bifonazole and everolimus, supporting their further investigation as antifungal agents for sporotrichosis in prospective hit-to-lead and preclinical investigations.

Keywords: Sporotrichosis ; Sporothrix brasiliensis ; Drug repurposing ; Structural bioinformatics ; Everolimus

Purchased from AmBeed: ; ; ; ;

Alternative Products

Product Details of Etoposide

CAS No. :33419-42-0
Formula : C29H32O13
M.W : 588.56
SMILES Code : O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]4O[C@H](C)OC[C@H]4O3)O)O)C5=C(C=C6OCOC6=C5)[C@@H](C7=CC(OC)=C(O)C(OC)=C7)[C@]21[H]
Synonyms :
VP-16; VP-16-213; NSC 141540
MDL No. :MFCD00869325
InChI Key :VJJPUSNTGOMMGY-MRVIYFEKSA-N
Pubchem ID :36462

Safety of Etoposide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335-H351-H361
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Etoposide

DNA

Isoform Comparison

Biological Activity

Description
Etoposide (VP-16; VP-16-213) is an anticancer chemotherapeutic agent. It functions by inhibiting topoisomerase II, thereby halting DNA replication. Etoposide induces cell cycle arrest, apoptosis, and autophagy [1].
Target
  • Topo II

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF7/VP cells 5 μM 18 h To evaluate the sensitivity of MCF7/VP cells to etoposide, results showed that CBLC4H10, CBLC4E10, and CBLC4E11 increased the sensitivity of cells to etoposide by 11.6-fold, 6.8-fold, and 7.7-fold, respectively PMC2746061
U2OS cells 68 μM 24 h To investigate the effect of RSF1 deficiency on etoposide-induced cell death, results showed that RSF1 deficiency significantly reduced cell death. PMC6197202
H1048 and H69 cells 1 µM Not mentioned To investigate the anticancer efficacy of Etoposide in combination with Silibinin and Cisplatin on small cell lung cancer (SCLC) cells PMC9532437
HeLa cells 50 µM 2 h Induced TOP2-DNA crosslinks and monitored SPRTN autocleavage PMC9867749
HeLa cells 100 µM Etoposide was used to induce cell death, and the results showed that it could cause apoptosis. PMC2193790
TC-32 cells 7.2 nM 2–8 h To investigate the effect of Etoposide on MRP-1 expression in TC-32 cells, results showed that Etoposide increased MRP-1 expression in the plasma membrane and mitochondria. PMC3304412
TC-32MRP-1.Fb-neo cells 7–240 nM 48 h To investigate the effect of Etoposide on the viability of TC-32MRP-1.Fb-neo cells, results showed that Etoposide significantly increased drug resistance in these cells. PMC3304412
H1299 cells 50 μM 24 hours To evaluate the effect of Pin1 on p53NLS-induced transcription-independent apoptosis, results showed that Pin1 co-expression significantly increased apoptosis induced by p53NLS. PMC3554345

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice TKO mouse model intraperitoneal injection 15 mg/kg on days 2 and 4 To evaluate the therapeutic effect of etoposide on tumors in TKO mice, results showed that etoposide increased tumor cell apoptosis and the proportion of Hes1-positive cells PMC5776014
Mice Neuroblastoma model Intraperitoneal injection 6 mg/kg Once daily for 5 consecutive days To evaluate the efficacy of etoposide in the neuroblastoma model, results showed that the combination of Reversan with etoposide significantly prolonged the survival time of mice compared to etoposide alone PMC2746061
Mice 4T1 breast cancer model Intraperitoneal injection 5 mg/kg Administered on day 7 and 12 To evaluate the effect of Etoposide on MDSC, results showed that Etoposide had limited effects on MDSC depletion PMC3896092
Mice Rsf1 conditional knockout mice Intraperitoneal injection 4 mg/kg Single dose, embryos treated at E15.0 To investigate the effect of Rsf1 deficiency on etoposide-induced DNA damage and apoptosis, results showed that Rsf1 deficiency significantly reduced apoptosis. PMC6197202
BALB/c nude mice Human small cell lung cancer (SCLC) xenograft model Intraperitoneal injection 12 mg/kg Once daily for 3 days To investigate the anticancer efficacy of Etoposide in combination with Silibinin and Cisplatin on small cell lung cancer (SCLC) xenograft models PMC9532437
Nude mice SCLC subcutaneous tumor model Intraperitoneal injection 4 mg/kg Once every 2 days To evaluate the antitumor effect of Etoposide on the SCLC subcutaneous tumor model, the results showed that Etoposide significantly inhibited tumor growth PMC7150483

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02179528 Small Cell Lung Cancer Extensi... More >>ve Stage Less << PHASE2 UNKNOWN 2025-09-17 Beijing Cancer Hospital, Beiji... More >>ng, Beijing, 100042, China Less <<
NCT00000807 Sarcoma, Kaposi|HIV Infections PHASE2 COMPLETED 2000-07-01 Univ of Alabama at Birmingham,... More >> Birmingham, Alabama, 35294, United States|K Norris Cancer Hosp / Los Angeles County - USC Med Ctr, Los Angeles, California, 900331079, United States|Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, 900331079, United States|San Francisco Gen Hosp, San Francisco, California, 941102859, United States|Denver Dept of Health and Hosps, Denver, Colorado, 80262, United States|Univ of Colorado Health Sciences Ctr, Denver, Colorado, 80262, United States|Yale Univ / New Haven, New Haven, Connecticut, 065102483, United States|Univ of Miami School of Medicine, Miami, Florida, 331361013, United States|Northwestern Univ Med School, Chicago, Illinois, 60611, United States|Indiana Univ Hosp, Indianapolis, Indiana, 462025250, United States|Boston Med Ctr, Boston, Massachusetts, 02118, United States|Adirondack Med Ctr at Saranac Lake, Albany, New York, 122083479, United States|Albany Med College / Division of HIV Medicine A158, Albany, New York, 122083479, United States|Mid - Hudson Care Ctr, Albany, New York, 122083479, United States|SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, 14215, United States|City Hosp Ctr at Elmhurst / Mount Sinai Hosp, Elmhurst, New York, 11373, United States|Saint Clare's Hosp and Health Ctr, New York, New York, 10019, United States|Mount Sinai Med Ctr, New York, New York, 10029, United States|Columbia Presbyterian Med Ctr, New York, New York, 100323784, United States|Julio Arroyo, West Columbia, South Carolina, 29169, United States Less <<
NCT04356690 COVID-19 PHASE2 TERMINATED 2022-07-01 Boston Medical Center, Boston,... More >> Massachusetts, 02118, United States Less <<
NCT04804007 Germ Cell Tumor|Non-seminomato... More >>us Germ Cell Tumor|Ovarian Germ Cell Tumor Less << PHASE2 RECRUITING 2025-12-28 Indiana University Melvin & Br... More >>en Simon Cancer Center, Indianapolis, Indiana, 46202, United States Less <<
NCT01492556 Breast Cancer PHASE2 UNKNOWN 2025-06-15 Beijing Hospital of the Minist... More >>ry of Health, Beijing, Beijing, 100005, China|Peking Union Medical College Hospital, Beijing, Beijing, 100005, China|Beijing Chao-yang Hospital, Beijing, Beijing, 100020, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, 100021, China|China-Japan Friendship Hospital, Beijing, Beijing, 100029, China|Peking University Cancer Hospital, Beijing, Beijing, 100142, China|Guangxi Cancer Hospital, Nanning, Guangxi, 530021, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116011, China|International Peace Maternity & Child Health Hospital of the China Welfare Institute, Shanghai, Shanghai, 200030, China|Shanghai Putuo District Center Hospital, Shanghai, Shanghai, 200062, China|Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830011, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China Less <<
NCT00000660 Sarcoma, Kaposi|HIV Infections PHASE1 COMPLETED 1992-07-01 San Francisco Gen Hosp, San Fr... More >>ancisco, California, 941102859, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, 10016, United States|Mem Sloan - Kettering Cancer Ctr, New York, New York, 10021, United States|Saint Luke's - Roosevelt Hosp Ctr, New York, New York, 10025, United States|Univ of Rochester Medical Center, Rochester, New York, 14642, United States|Julio Arroyo, West Columbia, South Carolina, 29169, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.70mL

0.34mL

0.17mL

8.50mL

1.70mL

0.85mL

16.99mL

3.40mL

1.70mL

References

 

Historical Records

Categories